Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
proton pump inhibitors + domperidone
- Development stage
- Unknown
- Lead developer
- Biological E
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination medication consisting of a proton pump inhibitor (PPI) and domperidone. The PPI component (such as omeprazole or pantoprazole) reduces gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells. Domperidone is a prokinetic agent that acts as a dopaminergic blocker, increasing lower esophageal sphincter pressure and enhancing gastric motility. This combination is primarily used to treat gastroesophageal reflux disease (GERD) and peptic ulcer disease, providing both acid suppression and improved gastric emptying. According to search results, this combination has shown superior efficacy in treating GERD symptoms compared to PPI monotherapy, including significant reduction in global GERD symptoms and potential improvement in esophagitis healing.
- Brand names
- Gaspaz DSOcid-DDomstal OOmidomRanidom NFDomped OZOmifluxOmerdOmlink-DOskar DSRPan-DPantocid DPantodac DDompanPandiffPantakind-DUlpan-DPansec DProtera DP2i-DP-2i-DP 2i-D
02
Targets
DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on proton pump inhibitors + domperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on proton pump inhibitors + domperidone.